8-KOther Events

BIOGEN INC. 8-K Report (Apr 14, 2004)

Filed April 14, 2004For Securities:BIIB

Summary

This 8-K filing from Biogen Inc. (BIIB) on April 14, 2004, primarily reports on the adoption of Rule 10b5-1 trading plans by two key executives: Executive Chairman William H. Rastetter and Executive Vice President of Human Resources Craig Eric Schneier. These plans allow for the scheduled sale of a predetermined number of company shares and stock options over specified periods. The disclosure is important for investors as it provides transparency regarding potential future selling activity by insiders.

Key Highlights

  • 1Executive Chairman William H. Rastetter has established two Rule 10b5-1 sales plans for shares held in trust and stock options.
  • 2Sales under Dr. Rastetter's plans are authorized to occur between June 10, 2004, and December 31, 2005.
  • 3The maximum number of shares Dr. Rastetter can sell across both plans is 184,081.
  • 4Executive Vice President Craig Eric Schneier has adopted a Rule 10b5-1 sales plan for stock options.
  • 5Sales under Mr. Schneier's plan are scheduled to take place between June 7, 2004, and May 31, 2005.
  • 6The maximum number of shares Mr. Schneier can sell under his plan is 122,500.
  • 7Rule 10b5-1 plans are pre-arranged trading plans designed to allow insiders to sell securities at predetermined times and prices, mitigating concerns about insider trading.

Frequently Asked Questions

A Rule 10b5-1 trading plan is a written document that allows company insiders (like executives and directors) to buy or sell company stock at a pre-determined time or based on predetermined criteria. These plans are designed to help insiders avoid accusations of insider trading by establishing a clear plan when they do not possess material non-public information.

Biogen is disclosing these plans as required by SEC regulations (specifically, Form 8-K). This transparency informs investors about potential future sales of Biogen stock by key executives, which can be relevant for understanding stock supply and demand dynamics.

No, the plans outline the maximum number of shares that *can* be sold. Executives can modify or terminate these plans under certain circumstances, and they are not obligated to sell the maximum amount. The plans provide a framework for potential future sales.

The total maximum number of shares that could be sold by Dr. Rastetter and Mr. Schneier under these plans is 184,081 (Dr. Rastetter) + 122,500 (Mr. Schneier) = 306,581 shares.